ABL-001 | 1492952-76-7
ABL-001 – A Branded Store
ABL001 by Surya - Abel ABL-001 10"H x 13"W x 13"D | Gamble Home Furnishings
ABL-001-Amide-PEG3-acid | Fluorescent Probe | MedChemExpress
eMolecules ABL-001 | 1492952-76-7 | | 5mg, Quantity: Each of 1 | Fisher Scientific
บาลัน HD video Balun 5MP 300เมตร ยี่ห้อARNOX | Lazada.co.th
ABL001 - GME
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 | Nature
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
ABL Bio
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 | Nature
Dual Drug Targeting of Mutant Bcr‐Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance - El Rashedy - 2018 - Chemistry & Biodiversity - Wiley Online Library
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
Asciminib, Supplier | ABL-001 | CAS 1492952-76-7 | ABL1 inhibitor | Sun-shinechem
Novartis receives FDA Breakthrough Therapy designations for STAMP inhibitor asciminib (ABL001)
Asciminib | C20H18ClF2N5O3 | CID 72165228 - PubChem
ABL Bio
ABL-001 | CAS# 1492952-76-7 | B1949 | BioVision, Inc.
BCR-ABL inhibitor asciminib (ABL001) meets phase 3 primary endpoint in CML | BLU Ampersand, Inc.
ABL 001, Asciminib | New Drug Approvals
Asciminib (ABL001) | 99.88%(HPLC) | In Stock | Bcr-Abl inhibitor
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 | Journal of Medicinal Chemistry
GME Antenna Base Universal with 4.5m Coaxial & PL259 - ABL001 - Accessories | Repco New Zealand
ABL kinases regulate the stabilization of HIF-1α and MYC through CPSF1 | PNAS
ABL 001, Asciminib | New Drug Approvals
